administr
immunosuppress
therapi
prevent
reject
allograft
graftversushost
diseas
although
necessari
render
transplant
recipi
suscept
opportunist
infect
group
transplant
patient
present
real
challeng
initi
diagnosi
infect
partli
due
lower
absent
marker
inflamm
tradit
infect
diagnos
use
bacteri
fungal
viral
cultur
well
varieti
immunolog
assay
method
still
remain
standard
care
diagnosi
infect
howev
seri
advanc
detect
techniqu
led
nucleic
acid
amplif
becom
promin
clinic
microbiolog
laboratori
novel
proteom
assay
current
ad
list
diagnost
tool
avail
infecti
pathogen
detect
identif
goal
chapter
review
tradit
molecular
method
use
diagnosi
infecti
diseas
transplant
patient
discuss
novel
methodolog
current
develop
potenti
impact
clinic
decis
cultur
remain
gold
standard
diagnosi
infecti
diseas
includ
caus
bacteria
mycobacteria
fungi
one
advantag
cultur
requir
priori
knowledg
specif
pathogen
respons
infect
cast
wide
search
net
use
multipl
growth
media
incub
condit
exampl
diarrhea
vomit
common
symptom
transplant
patient
determin
infecti
caus
symptom
challeng
due
confound
factor
intestin
graftversushost
diseas
gvhd
hematopoiet
stem
cell
transplant
hsct
recipi
neutropen
enterocol
immunosuppress
drug
request
bacteri
stool
cultur
allow
detect
common
caus
bacteri
gastroenter
name
salmonella
speci
shigella
speci
campylobact
speci
e
coli
recoveri
rate
rang
addit
bacteri
organ
grow
cultur
media
potenti
caus
gastrointestin
symptom
detect
report
howev
cultur
certain
organ
includ
c
difficil
common
caus
bacteri
diarrhea
hospit
patient
requir
special
cultur
media
setup
replac
part
nonculturebas
method
similarli
viral
caus
diarrhea
includ
cytomegaloviru
cmv
noroviru
adenoviru
rotaviru
small
round
virus
better
detect
nucleic
acid
amplif
test
naat
antigen
test
diagnost
yield
cultur
variou
specimen
type
remain
low
one
retrospect
studi
yield
bronchoalveolar
lavag
bal
fluid
cultur
diagnosi
pneumonia
bone
marrow
transplant
patient
report
bacteria
fungi
virus
respect
contrast
use
pcr
test
antigen
test
increas
overal
diagnost
yield
although
increas
detect
cmv
pcr
deem
clinic
signific
case
diagnost
yield
bal
studi
higher
one
studi
report
rate
detect
bacteria
fungi
virus
respect
cancer
patient
solid
organ
transplant
sot
overal
recoveri
pathogen
cultur
higher
lung
transplant
blood
cultur
import
diagnosi
bacteremia
fungemia
unfortun
yield
blood
cultur
remain
low
condit
current
blood
cultur
system
autom
set
continu
monitor
blood
cultur
detect
microorgan
except
continu
monitor
use
isol
tube
system
manual
lysiscentrifug
system
wampol
laboratori
cranburi
nj
perform
isol
tube
evalu
extens
autom
blood
cultur
system
design
improv
recoveri
fungi
mycof
lytic
bottl
bd
diagnost
spark
md
studi
show
increas
recoveri
h
capsulatum
c
neoforman
conclud
two
system
perform
equal
well
studi
creger
et
al
retrospect
analyz
perform
isol
tube
system
specif
cancer
popul
observ
advantag
convent
blood
cultur
method
even
use
isol
tube
detect
fungi
blood
cultur
low
biopsyproven
candidiasi
patient
posit
blood
cultur
transplant
patient
yield
blood
cultur
vari
type
transplant
degre
immunosuppress
lung
transplant
patient
yield
blood
cultur
high
aureu
p
aeruginosa
candida
speci
common
isol
recov
hsct
yield
vari
greatli
domin
gramposit
bacteria
major
fungal
isol
blood
cultur
candida
speci
c
albican
common
speci
isol
although
rare
noncandida
yeast
includ
trichosporon
speci
rhodotorula
speci
saccharomyc
cerevisia
recov
increas
frequenc
blood
cultur
immunocompromis
patient
fungemia
caus
mold
includ
aspergillu
speci
rare
detect
blood
cultur
patient
indwel
devic
mold
fusarium
paecilomyc
scedosporium
wangiella
recov
blood
cultur
recent
studi
limmathurotsakul
et
al
highlight
limit
cultur
diagnost
tool
imperfect
gold
standard
author
appli
bayesian
latent
class
model
lcm
establish
true
sensit
cultur
true
specif
four
serolog
test
detect
pathogen
use
burkholderia
pseudomallei
melioidosi
model
system
use
bayesian
lcm
either
condit
independ
ie
singl
test
consid
gold
standard
correl
among
test
condit
depend
ie
correl
among
test
sensit
cultur
estim
neg
predict
valu
specif
posit
predict
valu
four
serolog
test
increas
significantli
use
bayesian
lcm
model
emphas
limit
use
cultur
imperfect
gold
standard
recent
studi
defin
microbi
popul
variou
organ
use
deep
sequenc
highdens
sequenc
method
reveal
complex
microbi
organ
mani
noncultur
present
variou
tissu
differ
composit
transplant
versu
healthi
patient
signific
detect
noncultur
organ
infecti
diseas
manag
remain
establish
depend
degre
type
immunosuppress
transplant
patient
may
abl
mount
suffici
antibodi
respons
pathogen
limit
use
serolog
assay
detect
antibodi
hand
antigen
test
benefici
especi
fungal
infect
result
test
use
one
mycolog
criteria
defin
invas
fungal
diseas
ifd
commonli
use
antigen
test
includ
galactomannan
gm
antigen
produc
member
aspergillu
famili
bd
glucan
present
cell
wall
aspergillu
varieti
mold
yeast
serum
gm
assay
platelia
aspergillu
eia
biorad
laboratori
approv
unit
state
food
drug
administr
fda
assay
enzym
immunoassay
use
rat
monoclon
antibodi
detect
circul
gm
antigen
serum
gm
assay
evalu
extens
variou
patient
popul
sensit
rang
specif
rang
serum
greater
util
hsct
patient
sot
recipi
studi
jathavedam
colleagu
gm
assay
shown
limit
util
within
first
day
autosct
therefor
use
patient
manag
decis
anoth
studi
conduct
patient
hematolog
malign
sensit
gm
assay
invas
fungal
infect
caus
aspergillu
speci
fumigatu
ifd
caus
fumigatu
result
variou
studi
suggest
perform
gm
assay
depend
sever
factor
includ
infect
speci
aspergillu
type
transplant
popul
frequenc
test
durat
antifung
therapi
sensit
gm
assay
bal
hsct
recipi
patient
hematolog
malign
higher
report
serum
rang
use
optic
densiti
cutoff
valu
use
serum
solidorgan
transplant
patient
sensit
specif
gm
assay
bal
rang
respect
depend
optic
densiti
cutoff
valu
use
thu
gm
assay
bal
use
addit
test
diagnos
ifd
falseposit
result
observ
patient
receiv
piperacillin
amoxicillin
ticarcillin
without
betalactamas
inhibitor
patient
administ
electrolyt
replac
fluid
ie
plasmalyt
patient
infect
mold
aspergillu
low
specif
posit
predict
valu
howev
studi
vergidi
et
al
show
current
formul
piperacillintazobactam
appear
contamin
galactomannan
four
assay
fungitel
associ
cape
cod
inc
east
falmouth
cutoff
pgml
fungitecg
seikagaku
tokyo
japan
cutoff
pgml
wako
wako
pure
chemic
industri
tokyo
japan
cutoff
pgml
maruha
maruhanichiro
food
tokyo
japan
cutoff
pgml
commerci
avail
detect
bd
glucan
cell
wall
antigen
found
fungal
speci
cell
wall
exclud
mucormycet
cryptococcu
speci
recent
metaanalysi
review
studi
conduct
adult
hematooncolog
patient
show
similar
perform
four
assay
diagnosi
ifd
higher
diagnost
yield
perform
two
consecut
test
overal
low
sensit
high
specif
proven
probabl
ifd
anoth
metaanalysi
studi
includ
report
variou
patient
popul
sensit
specif
bd
glucan
test
respect
studi
conclud
bd
glucan
assay
use
adjunct
test
especi
diagnosi
ifd
due
candida
aspergillu
howev
recent
report
highfals
posit
patient
hematolog
malign
put
question
valu
test
standalon
test
diagnosi
ifd
sensit
bd
glucan
highest
diagnosi
pneumocysti
jirovecii
pneumonia
pcp
although
specif
nonhiv
immunocompromis
patient
vari
wide
therefor
result
test
taken
alon
conclus
make
diagnosi
pcp
howev
studi
shown
serum
bd
glucan
level
correl
well
p
jirovecii
fungal
load
bal
determin
pneumocysti
pcr
support
use
assay
monitor
respons
therapi
use
antigen
test
use
diagnosi
fungal
infect
includ
latex
agglutin
cryptococc
antigen
higher
sensit
central
nervou
system
infect
dissemin
diseas
urin
serum
antigen
endem
mycos
blastomyc
dermatitidi
histoplasma
capsulatum
antigen
although
crossreact
occur
among
target
diagnosi
viral
infect
replac
instanc
nucleic
acidbas
test
antigen
test
serolog
assay
method
direct
fluoresc
antibodi
dfa
stain
enzym
immunoassay
eia
still
play
part
diagnosi
certain
infect
includ
diagnosi
acut
chronic
hepat
infecti
mononucleosi
tcell
leukemia
one
common
viral
antigen
test
transplant
patient
cmv
antigen
monitor
viral
load
report
sensit
specif
cmv
antigenemia
test
vari
greatli
due
lack
standard
protocol
includ
specimen
process
monoclon
antibodi
use
slide
process
quantif
advantag
antigenemia
assay
includ
low
cost
term
reagent
equip
due
disadvantag
includ
need
rapid
specimen
process
laborintens
natur
assay
subject
read
slide
antigenemia
test
replac
mani
institut
molecular
test
monitor
cmv
viral
load
bacteri
antigen
test
import
transplant
patient
includ
urinari
antigen
test
legionella
pneumophila
serotyp
binax
scarborough
main
usa
streptococcu
pneumonia
binax
scarborough
main
usa
rapid
noninvas
test
use
diagnosi
commun
hospitalacquir
pneumonia
first
publish
polymeras
chain
reaction
pcr
report
describ
amplif
specif
target
sequenc
gene
diagnosi
sickl
cell
anemia
sever
modif
improv
occur
sinc
first
report
ultim
result
transfer
pcr
research
laboratori
clinic
diagnost
laboratori
altern
nucleic
acid
amplif
format
sinc
develop
includ
ligas
chain
reaction
lcr
nucleic
acid
sequencebas
amplif
nasba
branch
dna
bdna
signal
amplif
strand
displac
amplif
sda
helicasedepend
amplif
hda
loopmedi
amplif
lamp
numer
commerci
molecular
assay
approv
dfa
diagnosi
microbi
infect
transplant
patient
tabl
develop
realtim
pcr
combin
rapid
thermal
cycl
realtim
monitor
amplif
product
complet
revolution
practic
clinic
microbiolog
today
realtim
nucleic
acid
amplif
method
mainstream
section
clinic
microbiolog
impact
care
transplant
patient
signific
sever
realtim
pcr
laboratorydevelop
test
ldt
well
fdaapprov
assay
use
diagnosi
bacteri
infect
transplant
patient
bacteria
target
assay
develop
tradit
relat
nosocomi
infect
exampl
recent
pcr
assay
detect
c
difficil
ldt
assay
result
increas
sensit
turnaround
time
result
time
chapter
prepar
fda
clear
eight
molecular
assay
diagnosi
clostridium
difficil
infect
cdi
similarli
rapid
molecular
assay
develop
varieti
bacteri
target
includ
difficulttocultur
slowgrow
organ
ie
mycoplasma
pneumonia
chlamydophila
pneumonia
borrelia
burgdorferi
target
diagnosi
ie
group
streptococcu
throat
swab
nosocomi
pathogen
methicillinresist
aureu
methicillinsensit
aureu
vancomycinresist
enterococci
turnaround
time
identif
common
mycobacteria
speci
greatli
improv
introduct
nucleic
acid
hybrid
probe
laboratori
nucleic
acid
hybrid
probe
singlestrand
doublestrand
dnarna
fragment
complementari
sequenc
target
organ
commonli
label
fluoresc
chemiluminesc
marker
detect
probe
sameday
identif
tuberculosi
complex
kansasii
avium
complex
gordona
either
solid
liquid
cultur
commerci
avail
sinc
earli
genprob
san
diego
ca
probe
show
excel
sensit
specif
although
crossreact
report
tuberculosi
complex
terra
similar
probe
avail
identif
medic
import
filament
fungal
speci
current
trend
molecular
diagnosi
move
toward
syndrom
highli
multiplex
realtim
pcr
assay
newer
technolog
includ
variou
solid
liquid
microarray
format
current
fdaclear
molecular
syndrom
panel
avail
diagnosi
respiratori
tract
infect
bloodstream
infect
gastrointestin
infect
meningitisenceph
tabl
panel
differ
number
pathogen
detect
target
type
pathogen
includ
eg
bacteria
virus
yeast
level
complex
low
versu
high
turnaround
time
result
h
h
perform
characterist
howev
compar
sensit
specif
greater
compar
cultur
bidirect
sequenc
gold
standard
multiplex
bacteri
assay
avail
outsid
unit
state
exampl
lightcycl
septifast
roch
diagnost
gmbh
wienaustria
multiplex
realtim
pcrbase
assay
detect
bacteria
yeast
directli
whole
blood
agreement
septifast
blood
cultur
result
report
overal
conclus
current
form
assay
use
supplement
rather
replac
blood
cultur
method
septifast
assay
shown
especi
use
provid
addit
inform
immunocompromis
patient
includ
liver
transplant
septic
icu
patient
neutropen
patient
fungal
infect
case
prior
antibiot
administr
potenti
molecular
method
develop
evalu
diagnosi
bacteri
infect
includ
sequenc
quantit
loopmedi
isotherm
amplif
pcr
hybrid
mass
spectrometri
describ
previou
section
diagnosi
ifd
current
reli
microscop
examin
recoveri
mold
yeast
cultur
detect
fungal
antigen
includ
galactomannan
bd
glucan
variou
radiolog
find
pulmonari
infiltr
although
use
method
lack
specif
timeconsum
result
inconclus
find
studi
lin
et
al
suggest
earlier
diagnosi
fungal
infect
could
result
decreas
mortal
neutropen
cancer
patient
molecular
diagnosi
fungal
infect
reli
mostli
identif
organ
grow
cultur
nucleic
acid
hybrid
probe
identif
blastomyc
dermatitidi
histoplasma
capsulatum
coccidioid
immiti
cultur
isol
avail
sinc
earli
accuprob
genprob
san
diego
ca
sensit
rang
specif
near
hybrid
probe
rapid
demonstr
good
sensit
specif
cultur
although
crossreact
uncommon
fungal
organ
report
recent
peptid
nucleic
acid
fluoresc
situ
hybrid
pna
fish
probe
syndrom
panel
bloodstream
infect
filmarray
blood
cultur
id
panel
becom
avail
rapid
identif
c
albicanscandida
parapsilosi
c
glabratacandida
krusei
candida
tropicali
posit
blood
cultur
sever
realtim
pcr
assay
develop
last
year
vari
level
sensit
specif
often
limit
rang
target
candida
mold
speci
recent
shift
toward
develop
panfung
assay
observ
literatur
reflect
need
tool
detect
clinic
relev
fungal
pathogen
patient
specimen
recent
commerci
assay
reagent
becom
avail
detect
mold
directli
specimen
sever
assay
myconostica
ltd
uk
target
yeast
aspergillu
speci
pneumocysti
jirovecii
commerci
avail
outsid
unit
state
demonstr
high
sensit
specif
compar
cultur
ldt
assay
molecular
method
use
fungal
diagnosi
includ
sequencebas
identif
use
region
rrna
subunit
region
larg
ribosom
subunit
sever
studi
publish
show
util
sequenc
fungal
identif
laboratori
sequenc
complet
replac
use
phenotyp
method
identifi
fungi
grow
cultur
unlik
bacteria
fungi
molecular
method
detect
virus
well
establish
pathogen
consid
gold
standard
extens
literatur
develop
applic
molecular
assay
detect
virus
import
transplant
patient
includ
herpesvirus
epsteinbarr
virus
polyomaviru
bk
jc
viru
hepat
virus
respiratori
virus
one
first
applic
molecular
assay
virolog
includ
qualit
quantit
realtim
pcr
assay
diagnosi
monitor
human
immunodefici
viru
hiv
hepat
b
viru
hbv
hepat
c
viru
hcv
assay
extens
evalu
shown
use
manag
monitor
patient
infect
varieti
commerci
test
base
pcr
rtpcr
combin
sequenc
ie
trugen
genotyp
kit
viroseq
genotyp
system
hybrid
ie
innolipa
hbv
dr
avail
genotyp
resist
test
hiv
hbv
hcv
similarli
quantit
viral
load
test
develop
monitor
virus
import
variou
transplant
group
includ
cytomegaloviru
cmv
epsteinbarr
viru
ebv
bk
viru
jc
viru
adenovirus
howev
biggest
challeng
associ
use
laboratorydevelop
quantit
assay
inabl
compar
viral
load
result
obtain
across
laboratori
due
differ
genom
target
singl
vs
multicopi
gene
extract
method
manual
vs
autom
detect
platform
lack
intern
standard
calibr
limit
quantit
assay
made
establish
use
quantit
threshold
treatment
difficult
establish
recent
introduct
first
world
health
organ
intern
standard
cytomegaloviru
epsteinbarr
virus
well
avail
first
fdaapprov
commerci
realtim
quantit
assay
monitor
cmv
viral
load
aim
decreas
variabl
viral
load
measur
across
method
recent
studi
hayden
et
al
show
although
improv
standard
challeng
remain
field
use
molecular
assay
transplant
patient
includ
genotyp
assay
drug
resist
test
transplant
patient
often
prolong
antivir
therapi
patient
tend
develop
mutat
mutat
detect
realtim
pcr
assay
target
known
exist
mutat
confer
resist
certain
drug
ie
cmv
mutat
ganciclovir
sequenc
assay
detect
wildtyp
variant
sever
molecular
assay
receiv
fda
clearanc
detect
respiratori
virus
tabl
configur
assay
vari
singl
target
highli
multiplex
assay
first
fdaclear
multiplex
molecular
assay
respiratori
virus
respiratori
viral
panel
rvp
luminex
molecular
diagnost
toronto
canada
target
virus
subtyp
respiratori
syncyti
virus
b
influenza
subtyp
subtyp
untyp
influenza
b
parainfluenza
human
metapneumoviru
adenoviru
enterovirusrhinoviru
assay
provid
signific
improv
diagnosi
respiratori
viral
infect
compar
convent
method
instrument
rapid
diagnosi
influenza
outbreak
new
york
citi
addit
multiplex
molecular
assay
sinc
approv
includ
filmarray
respiratori
viral
panel
fa
rvp
biofir
diagnost
inc
salt
lake
citi
utah
fda
clear
detect
virus
subtyp
includ
viru
target
xtag
rvp
plu
human
coronavirus
parainfluenza
well
three
bacteri
target
bordetella
pertussi
chlamydia
pneumonia
mycoplasma
pneumonia
multipl
studi
publish
compar
highli
multiplex
assay
monoplex
assay
tradit
method
variou
patient
popul
result
shown
compar
perform
overal
sensit
specif
although
differ
detect
specif
target
includ
adenovirus
detect
higher
sensit
singl
target
assay
highli
multiplex
pcr
molecular
devic
detect
identif
panel
respiratori
viral
pathogen
also
commerci
avail
sever
manufactur
includ
genprob
prodess
assay
focu
diagnost
simplexa
assay
nanospher
inc
verigen
assay
parasit
interest
transplant
patient
especi
undergo
heart
transplant
toxoplasma
gondii
due
either
reactiv
latent
infect
acquisit
parasit
transplant
organ
unlik
immunocompet
host
diagnosi
toxoplasmosi
immunocompromis
patient
includ
transplant
recipi
effect
done
use
pcr
appropri
specimen
genom
assay
detect
microbi
organismspecif
nucleic
acid
therefor
posit
result
occur
aliv
dead
microorgan
particularli
true
pathogen
protect
cell
wall
best
exampl
detect
mycobacterium
tuberculosi
dna
sputum
dead
microbi
pathogen
dna
remain
undegrad
due
fatti
acidrich
cell
wall
unlik
result
functionbas
test
method
mycobacteri
cultur
clinic
set
posit
pcr
result
antituberculosi
therapi
necessarili
mean
treatment
failur
therefor
dnatarget
molecular
assay
usual
consid
test
cure
also
true
sexual
transmit
pathogen
chlamydia
trachomati
neisseria
gonorrhoea
posit
result
may
reflect
treatment
failur
persist
infect
may
also
reflect
resolv
infect
detect
mere
presenc
ribosom
rna
debri
nonviabl
c
trachomati
dna
overcom
disadvantag
transcriptom
assay
explor
abil
mrnabas
assay
distinguish
viabl
nonviabl
organ
suggest
assay
use
monitor
efficaci
antituberculosi
therapi
monitor
efficaci
therapi
mrna
rtpcr
result
parallel
well
cultur
followup
time
point
anoth
studi
demonstr
sputum
tuberculosi
mrna
reliabl
marker
bacteriolog
clearanc
respons
sever
mono
combin
antituberculosi
therapi
nucleic
acid
amplif
assay
target
microbi
mrna
also
use
diagnosi
assess
human
papillomaviru
hpv
infect
sever
report
shown
ubiquit
presenc
mrna
cervic
cancer
also
quantit
differ
overexpress
depend
sever
cervic
lesion
sever
mrna
qualit
assay
includ
aptima
genprob
nuclisen
easyq
hpv
pretect
hpvproofer
norchip
report
improv
low
specif
posit
predict
valu
hpv
dna
assay
advanc
molecular
biolog
technolog
especi
realtim
quantit
pcr
format
made
implement
mrnabas
assay
relev
accur
anoth
novel
approach
known
rnaseq
use
nextgener
sequenc
technolog
gener
transcriptom
profil
start
come
diagnost
microbiolog
field
use
dualspeci
transcript
profil
murin
model
system
candidiasi
hebeck
et
al
observ
delay
transcript
immun
respons
accompani
late
induct
fungal
stress
respons
gene
kidney
contrast
earli
upregul
proinflammatori
respons
liver
associ
fungal
transcriptom
resembl
respons
phagocytosi
suggest
phagocyt
contribut
significantli
fungal
control
liver
rasmussen
et
al
combin
longitudin
dimension
reduct
categor
analysi
transcriptom
liver
biopsi
specimen
taken
hcvinfect
patient
time
identifi
alter
gene
express
occur
histolog
evid
liver
diseas
progress
suggest
event
occur
acut
phase
infect
influenc
patient
outcom
contrast
fanci
advanc
technolog
transcriptom
assay
face
basic
specimen
sourcerel
challeng
current
limit
method
use
differenti
overcom
dna
contamin
mrna
target
test
theoret
specimen
pretreat
dnaas
prior
mrna
amplif
detect
howev
absolut
rnasefre
dnaas
rare
avail
actual
job
design
primersprob
cover
rna
splice
site
demonstr
effici
relev
rna
splice
site
avail
target
bacteria
virus
indirect
method
report
determin
antimicrobi
suscept
select
detect
viabl
microorgan
assay
use
dnabind
dye
penetr
damag
bacteri
cell
render
dna
unamplifi
therebi
decreas
background
amplif
kill
organ
one
lead
proteom
technolog
matrixassist
laser
desorpt
ionizationtim
flight
mass
spectrometri
malditof
ms
emerg
rapid
power
tool
microbi
speci
identif
analyt
molecul
embed
within
satur
matrix
target
plate
irradi
laser
special
wavelength
intens
induc
desorpt
ioniz
charg
analyt
acceler
electr
field
flight
tube
detector
captur
separ
variou
molecul
depend
time
flight
revers
proport
mass
molecul
detect
signal
process
interpret
mass
spectra
characterist
mass
peak
use
character
eventu
identifi
microorgan
measur
exact
size
peptid
small
protein
assum
characterist
bacteri
speci
possibl
determin
speci
within
minut
analysi
start
whole
cell
cell
lysat
crude
bacteri
extract
numer
report
shown
malditof
ms
revolution
routin
identif
microorgan
clinic
microbiolog
laboratori
introduc
easi
rapid
highthroughput
lowcost
effici
identif
techniqu
two
system
bruker
biotyp
bruker
dalton
inc
billerica
vitek
ms
inc
durham
nc
success
use
routin
clinic
microbiolog
laboratori
recent
compar
studi
perform
five
method
differenti
coagulaseneg
staphylococci
con
ie
gramposit
card
ref
id
staph
strip
partial
rrna
gene
sequenc
microseq
appli
biosystem
partial
tuf
gene
sequenc
inhous
malditof
ms
bruker
dalton
con
clinic
isol
malditof
ms
show
best
result
rapid
accur
con
differenti
strain
correctli
identifi
addit
microbi
identif
purifi
coloni
malditof
ms
success
use
directli
urin
posit
liquid
cultur
media
addit
rapid
identif
microorgan
malditof
ms
explor
determin
epidem
related
antibiot
resist
microbi
isol
util
malditof
ms
microbi
type
investig
staphylococcu
aureu
two
recent
studi
composit
correl
index
analysi
malditof
ms
data
demonstr
similar
interstrain
related
found
standard
type
method
use
confirm
outbreak
data
indic
technolog
potenti
rapid
screen
tool
nosocomi
infect
investig
malditof
ms
capabl
rapidli
accur
identifi
mecaposit
aureu
vanbposit
enterococcu
faecium
suscept
isol
malditof
ms
directli
use
determin
mechan
antibiot
resist
bittar
et
al
describ
use
malditof
ms
profil
clinpro
tool
softwar
detect
identifi
staphylococc
pantonvalentin
leukocidin
detect
identif
seri
gramneg
bacilli
malditof
ms
seem
power
quick
costeffect
method
clinic
microbiolog
laboratori
studi
repres
proof
concept
use
malditof
ms
technolog
rapid
method
time
monitor
microbi
infect
numer
proteom
biomark
use
diagnosi
monitor
microbi
infect
one
promis
biomark
recent
year
procalcitonin
pct
pct
mani
favor
properti
rapidli
induc
infect
long
halflif
capac
differenti
bacteri
viral
etiolog
use
valu
procalcitonin
sot
transplant
exist
literatur
suggest
reason
sensit
specif
pct
test
identifi
infect
complic
among
patient
undergo
transplant
monitor
pct
earli
posttranspl
period
seem
promis
method
earli
detect
infecti
complic
howev
given
imperfect
sensit
specif
pct
test
medic
decis
base
pct
test
result
clinic
find
recent
van
houten
et
al
report
use
threehost
protein
trail
crp
base
assay
differenti
bacteri
viral
infect
children
lower
respiratori
tract
infect
fever
without
sourc
diagnos
bacteri
infect
smell
practic
millennia
volatil
organ
compound
voc
produc
bacteria
metabolit
may
produc
differ
quantiti
combin
bacteri
speci
serovar
gener
characterist
odor
compound
combin
voc
could
use
volatil
fingerprint
bacterium
recent
fast
sensit
techniqu
led
varieti
mass
spectrometri
platform
develop
implement
detect
character
microbi
pathogen
base
microbi
metabolit
analysi
addit
metabol
analysi
use
function
character
includ
virul
resist
determin
gilreel
et
al
recent
examin
metabol
potenti
multidrugresist
uropathogen
escherichia
coli
demonstr
metabol
activ
member
lineag
correl
antibiot
suscept
profil
direct
detect
exogen
fungal
metabolit
breath
may
use
novel
noninvas
speciesspecif
approach
identifi
patient
invas
aspergillosi
ia
potenti
allow
precis
target
antifung
therapi
fewer
invas
diagnost
procedur
ga
chromatographi
coupl
mass
spectrometri
gcm
mainstay
detect
character
voc
produc
panel
gramneg
bacilli
uniqu
gcm
voc
found
produc
five
aspergillu
speci
fumigatu
versicolor
sydowii
flavu
niger
cultiv
malt
extract
agar
gypsum
board
anoth
studi
consist
detect
media
fumigatu
fusarium
spp
terreu
flavu
lesser
extent
niger
detect
breath
sampl
patient
cystic
fibrosi
fumigatu
colon
patient
cystic
fibrosi
microbiolog
evid
fumigatu
none
healthi
control
use
thermal
desorptiongcm
koo
et
al
character
vitro
volatil
metabolit
profil
fumigatu
pathogenspecif
metabol
signatur
combin
sesquiterpen
transgeranylaceton
accur
discrimin
patient
ia
patient
pneumonia
besid
aspergillu
speci
voc
nicotin
acid
found
promis
biomark
mycobacterium
tuberculosi
infect
pretranspl
evalu
donor
recipi
hsct
includ
serolog
determin
prior
exposur
pathogen
feder
accredit
cellular
therapi
fact
requir
donor
recipi
test
antibodi
hiv
human
tcell
lymphotrop
virus
ii
hbv
hcv
herp
virus
hsv
vzv
cmv
ebv
donor
recipi
test
exposur
west
nile
viru
trypanosoma
cruzi
donor
test
within
day
prior
collect
emerg
pathogen
potenti
transmiss
cellular
product
requir
develop
new
diagnost
assay
recent
exampl
zika
viru
non
fda
approv
test
current
use
screen
blood
donor
http
wwwcdcgovzikatransmissionbloodtransfusionhtml
howev
current
cdc
recommend
reduc
transmiss
zika
human
cell
cellularbas
product
base
epidemiolog
histori
http
base
result
pretranspl
test
clinician
assess
risk
benefit
altern
hsct
implement
prevent
treatment
exampl
recipi
posit
igg
antibodi
hepat
b
hbv
core
antigen
neg
hbv
surfac
ag
neg
hbv
pcr
treat
entecavir
prevent
reactiv
hbv
posttranspl
cmv
serolog
donor
recipi
major
implic
recipi
acut
cmv
infect
indic
posit
cmv
igm
neg
igg
transplant
may
delay
treatment
may
requir
cmv
serostatu
recipi
import
predictor
develop
cmv
infect
posttranspl
combin
result
donor
recipi
serolog
use
optim
donor
select
given
avail
sever
donor
similar
degre
hla
match
prefer
given
donor
match
cmv
serostatu
recipi
cmvseroneg
patient
use
cmvseroneg
donor
allevi
risk
cmv
transmiss
allograft
cmvseroposit
recipi
receiv
convent
allograft
cmvseroposit
donor
receiv
cmvspecif
cytotox
lymphocyt
ctl
contain
allograft
lymphocyt
cmvseroposit
donor
also
use
gener
ex
vivo
cmv
ctl
adopt
immunotherapi
posttranspl
cmv
serostatu
donor
recipi
also
determin
need
posttranspl
serial
monitor
cmv
recipi
cmv
posit
receiv
graft
cmvseroposit
donor
monitor
cmv
pcr
preemptiv
therapi
initi
cmv
infect
occur
anoth
approach
antivir
prophylaxi
cmv
highrisk
group
recipi
mismatch
tcelldeplet
allograft
interest
assess
whether
cmv
monitor
pcr
elimin
surviv
differ
cmvseroposit
cmvseroneg
recipi
addit
screen
may
indic
donor
recipi
tcelldeplet
graft
toxoplasma
serolog
requir
fact
test
per
institut
practic
patient
receiv
tcelldeplet
allograft
higher
risk
toxoplasmosi
compar
patient
receiv
convent
allograft
thu
recipi
tcelldeplet
allograft
may
candid
prophylaxi
toxoplasma
posttranspl
present
interpret
serolog
qualit
posit
vs
neg
recent
studi
suggest
magnitud
titer
may
relev
predict
diseas
risk
meer
et
al
report
high
titer
toxoplasma
igg
pretranspl
associ
increas
risk
toxoplasmosi
hsct
given
low
frequenc
toxoplasmosi
hsct
multicent
studi
would
requir
confirm
find
notion
magnitud
igg
titer
may
use
predictor
infect
posttranspl
also
support
pilot
studi
assess
pretranspl
antibodi
adenoviru
adv
studi
patient
high
pretranspl
igg
titer
specif
adv
serotyp
like
develop
adv
infect
adv
serotyp
hsct
patient
exposur
may
also
indic
need
addit
test
exampl
quantiferon
gold
test
detect
latent
tubercul
infect
pertin
transplant
candid
endem
area
tuberculosi
patient
latent
tubercul
infect
pretranspl
requir
treatment
posttranspl
pretranspl
stool
examin
ova
parasit
transplant
candid
come
endem
area
strongyloid
stercorali
empir
treatment
strongyloid
stercorali
pretranspl
could
employ
individu
cmv
import
caus
morbid
mortal
transplant
biolog
properti
natur
histori
cmv
well
defin
cmv
viremia
occur
frequent
hsct
instanc
preced
develop
endorgan
cmv
diseas
effect
antivir
treatment
avail
preemptiv
treatment
cmv
infect
shown
effect
prevent
endorgan
diseas
routin
monitor
recommend
patient
risk
cmv
diseas
current
pcrbase
assay
cmv
replac
antigenemia
assay
center
green
et
al
report
transit
preemptiv
therapi
strategi
antigenemia
pcrbase
monitor
host
risk
factor
success
prevent
cmv
diseas
without
increas
proport
patient
receiv
preemptiv
therapi
attribut
toxic
perform
characterist
individu
cmv
pcr
assay
vari
thu
cutoff
valu
threshold
treatment
compar
among
laboratori
avail
world
health
organ
intern
standard
cmv
nucleic
acid
amplif
techniqu
import
develop
decreas
varianc
laboratori
enabl
develop
intern
clinic
practic
guidelin
even
standard
assay
consider
variabl
iuml
differ
determin
viral
load
specimen
bk
polyomaviru
bkv
identifi
caus
allograft
nephropathi
kidney
transplant
bkvan
caus
hemorrhag
cystiti
hsct
recipi
renal
transplant
recipi
sever
studi
directli
link
bkv
replic
bkv
nephropathi
bkvn
bkv
viremia
predictor
bkvn
renal
allograft
furthermor
associ
magnitud
bkv
viral
load
blood
develop
bkvn
well
describ
appropri
cutoff
establish
clinic
signific
bkv
viremia
bkvn
case
report
hsct
recipi
diagnosi
bkvn
hsct
recipi
challeng
kidney
biopsi
oftentim
feasibl
due
thrombocytopenia
bleed
risk
exact
biolog
relationship
bkv
hemorrhag
cystiti
hct
recipi
well
understood
studi
shown
relationship
magnitud
urin
bkv
viral
load
develop
hemorrhag
cystiti
howev
concentr
viru
vari
wide
often
overlap
patient
develop
hemorrhag
cystiti
unfortun
effect
therapi
current
avail
prevent
treatment
symptom
associ
bkv
larg
part
due
lack
understand
etiolog
pathogenesi
like
pathophysiolog
cystiti
set
multifactori
bkv
reactiv
contribut
factor
level
bkv
viruria
hsct
exce
sever
log
level
observ
renal
transplant
reduct
immunosuppress
mainstay
manag
renal
transplant
option
allogen
hsct
due
risk
trigger
exacerb
graftversushost
diseas
despit
lack
establish
guidelin
interpret
bkv
pcr
result
hsct
pauciti
therapeut
measur
bkv
hsct
bkv
pcr
frequent
order
symptomat
patient
institut
prospect
monitor
adult
hsct
recipi
bkv
urin
qpcr
everi
week
begin
condit
week
posttranspl
found
patient
bkv
viruria
day
rate
remain
stabl
durat
studi
ten
patient
develop
hemorrhag
cystiti
grade
bedi
et
al
seven
patient
hemorrhag
cystiti
bkv
urin
two
concomit
adenoviru
univari
analys
high
bkv
viral
load
copiesml
older
age
predictor
hemorrhag
cystiti
studi
period
patient
die
patient
autopsi
perform
one
patient
found
bkvn
autopsi
find
suggest
factor
addit
bkv
like
involv
pathogenesi
hemorrhag
cystiti
posttranspl
present
recommend
monitor
asymptomat
patient
bkv
urin
patient
symptom
cystiti
identifi
etiolog
suggest
check
bkv
pcr
discourag
monitor
bkv
viral
load
urin
patient
known
bkv
viruria
bkv
nephropathi
consid
caus
renal
dysfunct
sever
immunosuppress
hsct
patient
without
obviou
etiolog
adenoviru
infect
occur
hct
recipi
depend
patient
age
type
transplant
degre
immunosuppress
advassoci
hepat
pneumon
enceph
frequent
fatal
coliti
hemorrhag
cystiti
caus
substanti
morbid
may
contribut
mortal
adv
serotyp
identifi
differ
term
frequenc
tropism
potenti
diseas
sever
adv
viremia
associ
decreas
overal
surviv
hsct
quantit
pcr
assay
adv
replac
part
cultur
antigen
assay
routin
surveil
adv
suggest
highrisk
patient
recipi
tcelldeplet
transplant
tcd
cord
blood
transplant
haploident
transplant
patient
refractori
gvhd
american
societi
bone
marrow
transplant
recommend
serial
monitor
adv
pcr
first
month
hsct
durat
sever
immunosuppress
andor
lymphopenia
patient
highest
risk
recommend
base
singlecent
experi
expert
opinion
valid
control
trial
ohrmalm
et
al
found
littl
util
serial
monitor
plasma
adv
pcr
cohort
hsct
compris
tcelldeplet
allograft
high
level
rise
adv
viremia
report
predict
dissemin
adv
diseas
death
rise
adv
viral
load
stool
also
report
use
predictor
adv
diseas
tcell
deplet
younger
age
gvhd
associ
invas
adv
diseas
cidofovir
use
establish
adv
diseas
adv
viremia
yet
efficaci
base
small
noncontrol
studi
case
seri
brincidofovir
novel
oral
administ
broadspectrum
antivir
activ
adv
shown
promis
result
case
report
small
random
placebocontrol
clinic
trial
preemptiv
treatment
adv
viremia
brincidofovir
confirm
antivir
activ
hct
patient
howev
subsequ
openlabel
phase
iii
studi
evalu
brincidofovir
treatment
local
dissemin
adv
infect
adult
pediatr
hsct
recipi
virolog
respons
correl
lower
adv
viral
load
start
treatment
earlier
start
brincidofovir
adv
diagnosi
gastrointestinalrel
abdomin
pain
diarrhea
nausea
vomit
symptom
common
advers
event
led
treatment
discontinu
especi
adult
hct
sinc
implement
routin
blood
pcr
monitor
posttranspl
tcd
cord
blood
hsct
recipi
rate
adv
viremia
virem
patient
develop
adv
diseas
tcd
hsct
recipi
adv
diseas
diagnos
within
day
posttranspl
patient
adv
diseas
die
benefit
preemptiv
therapi
adv
prevent
adv
diseas
recipi
tcd
graft
evalu
prospect
clinic
trial
infect
individu
first
month
life
resolut
primari
infect
viru
establish
latenc
mainli
cell
includ
monocyt
macrophag
altern
form
persist
integr
viral
sequenc
host
cell
chromosom
approxim
hsct
recipi
develop
reactiv
cord
rate
may
institut
select
hct
cord
blood
recipi
without
atg
develop
earli
viremia
rate
enceph
low
patient
cord
blood
respect
associ
host
indirect
consequ
acut
gvhd
cmv
reactiv
mortal
hsct
zerr
et
al
suggest
reactiv
associ
delirium
neurocognit
declin
hsct
recogn
sever
form
posttranspl
acut
limbic
enceph
pale
hill
et
al
examin
cohort
adult
donor
hsct
umbil
cord
transplant
identifi
risk
factor
pale
multivari
analys
cord
blood
transplant
grade
iiiv
gvhd
adult
mismatch
donor
signific
viral
load
higher
patient
pale
valu
greatli
overlap
furthermor
peak
valu
detect
median
day
day
form
symptom
onset
foscarnet
cidofovir
ganciclovir
avail
antivir
agent
demonstr
vitro
activ
control
trial
studi
agent
therapi
studi
evalu
efficaci
preemptiv
prophylact
therapi
prevent
pale
disappoint
infecti
complic
transplant
patient
often
extrem
complex
assess
sinc
wide
array
pathogen
caus
infect
includ
bacteria
virus
fungi
parasit
pattern
pathogen
infect
vari
tremend
particularli
set
hsct
immun
recoveri
play
major
role
defin
type
clinic
present
mani
infect
infect
may
occur
acut
event
pneumonia
bloodstream
infect
reactiv
latent
organ
case
herpesviru
infect
colon
without
true
invas
infect
recurr
nonrespond
resist
infect
furthermor
site
infect
may
local
singl
bodi
area
tissu
may
dissemin
hsct
recipi
may
suffer
immun
incompet
last
year
multiplex
assay
offer
advantag
quantiti
sampl
limit
provid
inform
multipl
pathogen
combin
multipl
diagnost
platform
sampl
test
sever
bodi
compart
cast
wider
net
expand
diagnost
capabl
present
specif
challeng
clinic
evalu
pulmonari
syndrom
hsct
patient
use
pcr
analyz
sampl
hsct
recipi
may
facilit
earli
detect
respiratori
virus
even
prior
onset
symptom
viral
load
like
low
symptomat
patient
pcr
test
provid
sensit
diagnost
approach
identifi
etiolog
respiratori
symptom
appropri
isol
ill
patient
addit
quantit
rtpcr
assay
use
initi
appropri
treatment
monitor
chang
viral
load
therapi
respiratori
virus
rsv
parainfluenza
virus
adenoviru
influenza
virus
known
caus
low
respiratori
infect
associ
substanti
morbid
mortal
immunosuppress
patient
contrast
correl
presenc
rhinoviru
coronaviru
upper
respiratori
tract
develop
lower
respiratori
infect
hsct
clear
correl
magnitud
viral
load
bronchoalveolar
lavag
fluid
pneumonia
transplant
outcom
current
investig
varieti
virus
use
nucleic
acid
assay
may
contribut
identif
organ
previous
associ
pulmonari
diseas
enteroviru
recent
associ
acut
respiratori
distress
syndrom
infant
hsct
human
metapneumoviru
hmpv
human
bocaviru
report
caus
sever
lower
respiratori
tract
infect
two
new
human
polyomavirus
ki
polyomaviru
kipyv
wu
polyomaviru
wupyv
found
one
third
allogen
hsct
recipi
respiratori
specimen
first
year
posttranspl
associ
respiratori
symptom
unclear
diagnos
invas
pulmonari
aspergillosi
ipa
remain
challeng
tissu
diagnosi
ideal
yet
invas
procedur
may
feasibl
critic
ill
patient
especi
cytopenia
isol
aspergillu
speci
bal
may
repres
colon
invas
infect
depend
speci
clinic
context
exampl
aspergillu
versicolor
aspergillu
niger
often
associ
diseas
isol
bal
specimen
cytolog
combin
tradit
cultur
techniqu
may
improv
diagnost
yield
retrospect
studi
compar
diagnost
yield
cytolog
cultur
septat
mold
infect
cytolog
bal
bronchial
wash
specimen
higher
yield
compar
cultur
tissu
autopsi
biopsi
sampl
vs
p
noninvas
sensit
test
need
diagnosi
mold
infect
detect
aspergillu
secondari
metabolit
signatur
simpl
breath
test
show
sensit
specif
diagnosi
ipa
small
preliminari
studi
test
offer
promis
altern
patient
undergo
bronchoscopi
molecularbas
assay
expect
allow
rapid
diagnosi
aspergillu
nonaspergillu
invas
fungal
infect
high
sensit
recent
multicent
prospect
studi
evalu
addit
pcr
gm
bal
sampl
improv
diagnosi
invas
aspergillosi
initi
valid
studi
serum
gm
assay
report
sensit
specif
probabl
proven
ipa
howev
sensit
serum
gm
consider
lower
set
moldact
azol
prophylaxi
determin
gm
bal
fluid
may
improv
diagnost
util
assay
prospect
cohort
studi
includ
patient
hematolog
malign
sensit
specif
bal
gm
detect
probabl
proven
ipa
prospect
studi
need
combin
two
diagnost
modal
diagnosi
proven
probabl
aspergillosi
fungal
pcr
use
confirm
diagnosi
invas
fungal
infect
tradit
cultur
neg
especi
patient
previous
treat
antifung
agent
institut
among
patient
particip
random
trial
antifung
prophylaxi
fungal
infect
neutropen
patient
undergo
induct
reinduct
chemotherapi
six
patient
underw
bronchoscopi
evalu
pulmonari
infiltr
bal
test
cytolog
tradit
fungal
cultur
gm
univers
fungal
pcr
none
patient
posit
fungal
cultur
posit
gm
bal
fungal
pcr
identifi
rhodotorula
nogopathi
cryptococcu
saitoi
one
patient
fungi
recogn
previous
pathogen
human
patient
respond
clinic
antifung
therapi
adjust
target
organ
tradit
cultur
techniqu
routin
use
diagnosi
candidemia
clinic
relev
noncandida
speci
isol
blood
interpret
caution
retrospect
studi
noncandida
fungemia
episod
allogen
hsct
recipi
patient
clinic
signific
fungemia
monitor
viral
load
assess
respons
treatment
wellestablish
practic
cmv
cmv
viral
replic
blood
usual
correl
diseas
activ
depend
cmv
viral
load
clinician
may
continu
treatment
chang
dose
type
antivir
discontinu
treatment
less
evid
exist
correl
adv
viral
load
diseas
activ
yet
clinician
routin
use
viral
load
aid
treatment
decis
monitor
viral
load
respiratori
virus
prognost
indic
lower
respiratori
tract
infect
hsct
patient
routin
clinic
practic
present
recent
studi
suggest
approach
may
valu
genotyp
assay
antivir
resist
may
offer
clinic
guidanc
time
fashion
commerci
avail
assay
avail
cytomegaloviru
resist
usual
emerg
prolong
subtherapeut
exposur
antivir
set
immunosuppress
cmv
resist
current
antivir
agent
mediat
alter
either
kinas
dna
polymeras
encod
gene
respect
mutat
capabl
confer
resist
ganciclovir
mutat
impart
resist
ganciclovir
cidofovir
foscarnet
studi
correl
cmv
genotyp
drug
suscept
phenotyp
may
guid
treatment
decis
improv
interpret
sequencebas
assay
current
use
clinic
diagnosi
guid
develop
new
antivir
drug
resist
influenza
viru
antivir
agent
concern
immunocompromis
hsct
patient
due
high
grade
prolong
viral
replic
prolong
exposur
antivir
rapid
identif
emerg
resist
treatment
would
help
modifi
treatment
patient
invas
aspergillosi
posit
serum
gm
baselin
serial
monitor
serum
gm
provid
use
inform
respons
treatment
prognosi
koo
et
al
report
combin
gm
baselin
week
predict
allcaus
mortal
independ
tradit
risk
factor
mortal
antifung
exposur
prospect
studi
bergeron
et
al
show
poor
day
outcom
strongli
associ
high
baselin
serum
gm
index
ii
consist
neg
serum
gm
index
followup
associ
good
outcom
contrast
either
steadi
emerg
posit
gm
index
iii
day
clinic
evalu
predict
day
outcom
patient
treat
aspergillosi
rise
gm
level
initi
normal
rais
concern
breakthrough
infect
inadequ
exposur
develop
resist
ongo
antifung
therapi
last
decad
nucleic
acidbas
assay
enhanc
diagnost
sensit
specif
shorten
test
turnaround
time
provid
automat
highthroughput
process
enabl
quantif
microbi
pathogen
posit
molecular
test
result
indic
target
pathogenspecif
nucleic
acid
detect
opportunist
pathogen
particular
clinic
interpret
crucial
determin
clinic
signific
posit
test
evolv
genom
transcriptom
proteom
metabolom
technolog
translat
clinic
applic
fast
pace
collabor
laboratori
clinic
medicin
paramount
ensur
optim
util
interpret
diagnost
modal
